Memantinhydrochlorid Doc Generici

Memantine Hydrochloride, the active ingredient in Memantinhydrochlorid Doc Generici, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients with moderate to severe cognitive impairment.

GNH USA supplies Memantinhydrochlorid Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Memantine Hydrochloride is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition, daily functioning, and slows symptomatic decline. Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression. Alzheimer’s disease (overall progression): helps to stabilize disease course when used with standard care.

Memantine Hydrochloride may be associated with a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Fatigue: feeling of tiredness that may improve over time. - Hypertension: occasional increase in blood pressure. - Confusion: transient disorientation, particularly in elderly patients.

Serious or Rare Side Effects: - Seizures: rare but may occur, requiring immediate medical attention. - Severe rash or skin reactions: including Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Suicidal thoughts: emergent mood changes warranting urgent evaluation. - Cardiac arrhythmias: uncommon but serious rhythm disturbances.

When prescribing Memantine Hydrochloride, clinicians should consider several safety aspects.

Renal impairment: assess kidney function before initiating therapy. Hepatic impairment: monitor liver enzymes regularly. History of seizures: use with caution and monitor for seizure activity. Concurrent use with other NMDA antagonists: may increase neuropsychiatric effects. Store below 25°C: keep in the original pack, protect from moisture.

Memantine Hydrochloride can interact with other medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may exacerbate neurotoxicity. - Other NMDA antagonists (e.g., ketamine): increased risk of central nervous system adverse effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefit. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation. - Diuretics: may potentiate hypotensive effects.